POPULARITY
15 episodes with Pharmacokinetics
20 episodes with Pharmacokinetics
3 episodes with Pharmacokinetics
4 episodes with Pharmacokinetics
3 episodes with Pharmacokinetics
3 episodes with Pharmacokinetics
2 episodes with Pharmacokinetics
3 episodes with Pharmacokinetics
2 episodes with Pharmacokinetics
Episode Description:In this special edition of The New Chemist's Podcast, host David Ferguson brings you a three‑part journey:Around the World with Gary ArndtWe kick off with an in‑depth interview featuring award‑winning travel blogger, photographer, and podcaster Gary Arndt of Everything Everywhere Daily. Discover how Gary sold his home in 2007 to explore 190 countries, built a daily history podcast with nearly 2 million downloads, and turned storytelling into a global classroom .Bilingual Break: Langer & May in JapaneseNext, immerse yourself in a Japanese translation of highlights from Dr. Robert Langer and Dr. Matthew May's groundbreaking conversation. Whether you're strengthening your language skills or simply curious about how leading scientists share ideas across cultures, this segment bridges East and West.Pharmacokinetics FundamentalsFinally, sharpen your clinical toolkit with a clear, step‑by‑step primer on the fundamentals of pharmacokinetics. We'll unpack absorption, distribution, metabolism, and excretion—arming you with the core concepts every pharmacist and researcher needs.Tune in for an episode that spans continents, languages, and the science of drug movement through the body. Whether you're a travel enthusiast, a language learner, or a pharmacy professional, there's something here for everyone.
Avec Dre Julie Autmizguine, pédiatre-infectiologue, et Stéphanie Tremblay, pharmacienne en pédiatrie générale et en maladies infectieuses, nous allons:définir l'ostéomyélite et l'arthrite septique (définition, physiopathologie, agents pathogènes, diagnostic, complications possibles);décrire les différentes options de traitements (chirurgical, médical);illustrer les notions abordées via des cas patients afin de répondre à des questions pratiques.Références:Société canadienne de pédiatrie. Le diagnostic et la prise en charge des infections ostéoarticulaires aiguës chez les enfants. 2018. Reconduit en janvier 2024. The Royal Children's Hospital Melbourne. Clinical Practice Guideline: Bone and joint infection. Mis à jour en 2021. Peltola H et al. Osteomyelitis-Septic Arthritis Study Group. Short- versus long-term antimicrobial treatment for acute hematogenous osteomyelitis of childhood: prospective, randomized trial on 131 culture-positive cases. Pediatr Infect Dis J. 2010 Ballock RT et al. A comparison of early versus late conversion from intravenous to oral therapy in the treatment of septic arthritis. J Pediatr Orthop. 2009 Autmizguine J et al. Pharmacokinetics and pharmacodynamics of oral cephalexin in children with osteoarticular infections. Pediatr Infect Dis J. 2013Nielsen AB et al. Oral versus intravenous empirical antibiotics in children and adolescents with uncomplicated bone and joint infections: a nationwide, randomised, controlled, non-inferiority trial in Denmark. Lancet Child Adolesc Health. 2024 Alcobendas Rueda RM et al. Oral Versus Intravenous Antibiotics for Pediatric Osteoarticular Infection: When and to Whom? Pediatr Infect Dis J. 2022 Keren R et al. Pediatric Research in Inpatient Settings Network. Comparative effectiveness of intravenous vs oral antibiotics for postdischarge treatment of acute osteomyelitis in children. JAMA Pediatr. 2015 AntibioPed. (2025) Messil inc. (Version 1.5.0) [Application mobile] Disponible sur l'AppStore et Google Play. Également disponible en version web.Captation et montage: Philippe Lacroix, spécialiste en audiovisuelIdée originale, réalisation et animation: Émilie Roy-St-PierreConseillères en communication: Katrine Louis-Seize et Pascale ChatagnierLogo: Équipe des communications et du graphisme du CHU Sainte-JustineMusique: Samuel Ross Collègues, ami(e)s et famille, merci pour votre précieux soutien. © mgparkilo 2025Merci pour l'écoute! Allez mettre une réaction sur vos épisodes préférés, partagez la bonne nouvelle sur Facebook/Instagram et abonnez-vous pour ne rien manquer
Pour accéder à l'intégralité de ce podcast et écouter chaque semaine un nouvel épisode du Quart d'Heure Véto, c'est très simple, il vous suffit de vous abonner en cliquant sur ce lien : https://m.audiomeans.fr/s/S-yUNSBZSR Notes et référencesArticle : Mercer MA, Davis JL, McKenzie HC, Byron CR, Kelleher ME, Trager L, Cecere TE, Wilson KE, Council-Troche RM, Werre SR. Pharmacokinetics, clinical efficacy and safety of acetaminophen (paracetamol) in adult horses with naturally occurring chronic lameness. Equine Vet J. 2024 Jan;56(1):202-214. doi: 10.1111/evj.13959. Epub 2023 Jun 7. PMID: 37287331.Retrouvez toute la synthèse sur la fiche podcast juste ici : https://audmns.com/UmSeyprPour nous suivre :1. Abonnez-vous à notre chaine pour profiter de l'intégralité des épisodes : Le Quart d'Heure Véto : décrypte et résume en moins de 15 min un article de biblio véto - Sur abonnement uniquementLe Véto du Mois : Partagez le temps d'une interview l'expérience de vétérinaires emblématiques de notre milieu, des rencontres conviviales, comme si nous étions dans votre salon au coin du feu. Podcasts bonus au fil des inspirations... 2. Le ScopeNous partageons avec vous nos dernières découvertes, inspirations, pistes de réflexion, nouveautés… À découvrir et utiliser dès maintenant, TOUT DE SUITE, dans votre quotidien de vétérinaire, de manager, de vie personnelle, de chef d'entreprise… Et tout cela en moins de 5 minutes top chrono un à 2 mardis par mois ! Je souhaite recevoir mon Scope : https://vetmasterclass.com/lescope/ 3. Contactez-nous, suivez-nous et donnez nous votre avis ! Des sujets que vous souhaiteriez approfondir, des références à partager, ou nous faire part de vos feed-backs :Abonnez-vous à notre chaine, donnez nous des étoiles, un commentaire et partagez autour de vous !Sur notre site : https://vetmasterclass.com/Sur Facebook : https://www.facebook.com/VmHorseSur Instagram : https://www.instagram.com/vetmasterclass/Sur YouTube : https://www.youtube.com/channel/UC18ovcWk9e-mFiTL34OQ03gSur Linkedin : https://www.linkedin.com/company/vetmasterclass-horse/about/Belle journée à tous, Et continuez à vivre votre métier avec Passion ! Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.
Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to discuss promising topline results from the company's Phase 1, single ascending dose trial of TNX-1500 in healthy participants. The trial evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TNX-1500 and was designed to support dosing for an upcoming Phase 2 trial in kidney transplant recipients. Two published studies in the American Journal of Transplantation demonstrated that TNX-1500 can prevent rejection, prolong survival, and preserve graft function in non-human primate renal and heart allografts, either as a single agent or in combination with other therapies. Dr. Lederman shared that Phase 1 results showed TNX-1500 at 10 mg/kg and 30 mg/kg doses effectively blocked both primary and secondary antibody responses to a test antigen. Pharmacokinetic data suggest that monthly dosing at 10 mg/kg or higher could be effective. These findings reinforce the company's confidence in TNX-1500's potential to prevent organ transplant rejection and improve graft survival with a lower long-term toxicity burden compared to existing immunosuppressive therapies. Tonix plans to present these results to the U.S. Food and Drug Administration (FDA) in an End-of-Phase 1 meeting. Pending FDA alignment, the company will move forward with a Phase 2 efficacy study in kidney transplant recipients. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #TonixPharmaceuticals #Biotech #FDA #FDAApproval #TNX1500 #MonoclonalAntibodies #OrganTransplant #AutoimmuneDisease #MedicalResearch #PharmaNews #HealthcareInnovation
Dr. Becca Bruning, Infectious Diseases Pharmacy Specialist at the Moffitt Cancer and Research Institute in Tampa, FL, takes a deep dive into the subject of resistance mechanisms for specific gram negative bacteria. Dr. Bruning begins her talk by discussing the primary resistance mechanisms, including porin channels, efflux pumps, and other target sites. Extended spectrum beta-lactamases (ESBLs) are next covered, including typical bacterial species, identification techniques, ESBL testing, and the use of Piperacillin-tazobactam and carbapenems. Next, Dr. Bruning mentions AmpC-type resistance, and identifies the “HECKYES” bacteria. Pharmacokinetic and phamacdynamic considerations are explored, and specific antimicrobial agents are discussed. Lastly, Dr. Bruning covers the use of carbapenemase testing including the modified hodge test and the Carba-R test.
In this episode of Onc Now, Jonathan welcomes Ahmad Awada, Head of the Oncology Department at Chirec Cancer Institute in Brussels and Editor in Chief of EMJ Oncology. Together they discuss groundbreaking developments in cancer care, the promise of targeted therapies, and the importance of global collaboration in oncology. Timestamps: (00:00)-Introduction (01:20)-Reflecting on ESMO 2024 (07:37)-Looking ahead to ESMO 2025 (10:04)-Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates (13:24)-New cytotoxics and molecular targeted therapies for solid tumours (16:30)-Surgery of primary tumour in de novo metastatic breast cancer (19:29)-Improving survival in cancer patients (22:47)-Managing the risk of thromboembolism (24:43)-Exciting advancements on the horizon (29:38)-Wishes for oncology
In this episode, we review the high-yield topic of Pharmacokinetics from the Pharmacology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets
Xylazine Pharmacokinetics in Patients Testing Positive for Fentanyl and Xylazine Clinical Chemistry This study of xylazine pharmacokinetics used plasma samples from 28 patients who had urine screens positive for xylazine and fentanyl. The patients were being treated for skin lesions, most commonly, then shortness of breath or opioid overdose. At least two subsequent plasma samples were analyzed for xylazine and xylazine metabolites by LC-MS/MS. The median terminal half-life for xylazine in plasma was 12 hours (range 6-21 hours). Animal studies show xylazine to be extensively metabolized, with little unchanged xylazine eliminated in urine. The two most abundant metabolites were oxo-x and sulfone-x, which did not have a window of detection longer than xylazine. Researchers had no information as to the timing or route of xylazine ingestion or if additional xylazine was consumed during the study period. These factors could affect the accuracy of the results. Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM
Episode 59 – Detomidine OTM Gel – The perfect PVP Protocol for Zack! I really wanted to share Zack's story as I get asked so many questions about how best to handle very fearful and potentially aggressive canine patients in the veterinary setting. The answer is - there is no simple or blanket answer – and every patient must be treated and considered as an individual. It helps, of course, if you have many different tools in your toolbox and you have the knowledge and experience to use these tools wisely and to select the right tool for the right patient. In Zack's case this was detomidine oral trans-mucosal gel, an equine sedative that can absolutely be safely used in dogs, if you know how. Zack's caregiver was able to apply the gel while playing with Zack before he came to the clinic, and I was then easily able to administer an intra-muscular sedative to facilitate the examination and veterinary care he needed. Here are the papers on the use of detomidine OTM gel in dogs originally published by Dr Hopfensperger in 2013 and 2016, but the doses in these have been superseded in a recent abstract, which was presented at the Veterinary Behaviour Symposium in 2023. 1. Hopfensperger, M. J., Messenger, K. M., Papich, M. G., & Sherman, B. L. (2013). The use of oral transmucosal detomidine hydrochloride gel to facilitate handling in dogs. Journal of Veterinary Behavior: Clinical Applications and Research, 8(3), 114–123. https://doi.org/10.1016/j.jveb.2012.10.004 2. Messenger, K. M., Hopfensperger, M., Knych, H. K., & Papich, M. G. (2016). Pharmacokinetics of detomidine following intravenous or oral-transmucosal administration and sedative effects of the oral-transmucosal treatment in dogs. American Journal of Veterinary Research, 77(4), 413–420. https://doi.org/10.2460/ajvr.77.4.413 If you would like to schedule a vet to vet or vet to pet care professional call, follow the link below: https://calendly.com/trinityvet/teams-and-professionals I really hope you enjoy this episode; it is packed with so much information! If you liked this episode of the show, The Pet Behaviour Chat, please LEAVE A 5-STAR REVIEW, like, share, and subscribe! Facebook Group: Join The Pet Behaviour Community on Facebook You can CONNECT with me: Website: Visit my website Trinity Veterinary Behaviour Instagram: Follow Trinity Veterinary Behaviour on Instagram Trinity Veterinary Behaviour Facebook: Join us on Trinity Veterinary Behaviour's Facebook page Trinity Veterinary Behaviour YouTube: Subscribe to Trinity Veterinary Behaviour on YouTube LinkedIn Profile: Connect with me on LinkedIn Thank you for tuning in!
We sit down with one of our toxicologists to discuss acetaminophen toxicity. Hosts: Marlis Gnirke, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Acetaminophen_Toxicity.mp3 Download One Comment Tags: Toxicology Show Notes Table of Contents 0:35 – Hidden acetaminophen toxicity in OTC products 3:24 – Pharmacokinetics and toxicokinetics 6:06 – Clinical Course 9:22 – The antidote – NAC 11:02 – The Rumack-Matthew Nomogram 17:36 – Treatment protocols 22:34 – Monitoring and Lab Work 23:23 – Considerations when treating pediatric patients 23:57 – IV APAP overdose, fomepizole 25:42 – Take Home Points Acetaminophen vs. Tylenol: The importance of recognizing that acetaminophen is found in many products beyond Tylenol. Common medications containing acetaminophen, such as Excedrin, Fioricet, Percocet, Dayquil/Nyquil, and others. The risk of unintentional overdose due to combination products. Prevalence of Acetaminophen Toxicity:
In this episode of the RWS Clinician's Corner, Margaret Floyd Barry meets with one of the world's top supplement formulators, Shawn Wells. Not only does Shawn give us the inside scoop on some really powerful new supplement ingredients and formulations, but he delves into the complex process of creating supplements, improving their bioavailability, and the science behind new, innovative ingredients on the market. We also explore the exciting world of exercise mimetics and their potential health benefits, especially for those unable to train due to severe health conditions. Plus, you'll hear about the exciting new ingredient, paraxanthine, and how it might soon revolutionize the market. We discuss: The supplement formulation process, with an emphasis on quality control and compliance How Shawn thinks about developing novel ingredients Dihydroberine, L-ergothioneine & Spermidine: what they do and why they're important NAD and aging Benefits of Paraxanthine and Dileucine Using Creatine for health (not just building muscle) - one of Shawn's top recommendations Blood sugar management with Dihydroberine (vs. Metformin) Supplement integrity: key things to watch out for when researching a new product or line The Clinician's Corner is brought to you by Restorative Wellness Solutions. Follow us: https://www.instagram.com/restorativewellnesssolutions/ Timestamps: 00:00 Mother sold Shackley vitamins; early supplement industry. 06:21 Vitamin C research explores higher doses, benefits. 15:57 Paraxanthine benefits without caffeine's side effects. 20:23 Attention to detail signifies brand quality control. 27:31 Supplements: Can't claim cures, only support wellness. 29:04 High-earning products must be tailored to individuals. 35:04 Restorative Wellness Solutions: Transformative health practitioner training. 43:44 Mitochondrial health is crucial for combating aging. 48:07 NAD declines with age; polyphenols inhibit breakdown. 51:39 No caffeine side effects; boosts nitric oxide, dopamine. 59:44 Optimize leucine spikes for protein synthesis effectiveness. 01:01:53 Mitochondria abundance supports high energy cells. 01:06:51 Join, follow, share, suggest topics, change health. Speaker bio: Shawn Wells MPH, LDN, RD, CISSN, FISSN is the world's leading nutritional biochemist and expert on health optimization. He has formulated over 700 supplements, food, beverages, and cosmeceuticals and patented 20 novel ingredients including Teacrine, Dynamine and Dihydroberberine and is now known as the “ingredientologist” - the scientist of ingredients. Formerly a Chief Clinical Dietitian with over a decade of clinical experience, he has counseled thousands of people on innovative health solutions such as keto, paleo, fasting, and supplements. He has also personally overcome various health issues including Epstein-Barr Virus, Chronic Fatigue Syndrome, Fibromyalgia, depression, insomnia, obesity, and a pituitary tumor. As a world-renowned thought-leader on mitochondrial health, he has been paid to speak on five different continents. His insights have been prominently featured in documentaries and podcasts like Ben Greenfield and regularly on morning television. His expertise can help any health-conscious individual to better manage stress and experience greater resilience and more energy through utilizing his practical research-backed solutions. His book, The Energy Formula, has been recognized by both USA Today and Forbes as well as an Amazon best-seller in multiple categories. Connect with Shawn Wells: Website: https://shawnwells.com/ Instagram: https://www.instagram.com/shawnwells/ And find his book, The Energy Formula, here. Keywords: supplement formulation, Shawn Wells, dihydroberine, paraxanthine, bioavailability, pharmacokinetics, cognitive function, physiological benefits, metformin alternatives, CGMP certification, exercise mimetics, L-valine, Albeba, insulin sensitivity, mitochondrial health, longevity vitamins, L-ergothioneine, spermidine, anti-aging supplements, NAD levels, NMN vs NR, apigenin, fisetin, autoimmune diseases, gluten sensitivities, paresthesis, caffeine metabolites, dileucine, continuous glucose monitor, acetyl-L-carnitine, creatine Disclaimer: The views expressed in the RWS Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of Restorative Wellness Solutions, LLC. Restorative Wellness Solutions, LLC does not specifically endorse or approve of any of the information or opinions expressed in the RWS Clinician's Corner series. The information and opinions expressed in the RWS Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. Restorative Wellness Solutions, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the RWS Clinician's Corner series. By viewing or listening to this information, you agree to hold Restorative Wellness Solutions, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.
Send us a textMichael Demurjian is CEO And Chairman of Aspargo Labs ( https://aspargolabs.com/ ), which he co-founded in 2019, which is a distinguished pharmaceutical and med-tech company committed to developing innovative oral spray formulations and drug delivery systems.Mr. Demurjian brings extensive experience across finance, manufacturing, sales & marketing, logistics, and general management. He has experience in taking companies public, raising funds in public and private markets with both retail and institutional investors. Prior to Aspargo Labs, Mr. Demurjian served as COO, CFO and member of the Board of Directors of Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. At Tyme, Mr. Demurjian was instrumental in raising over 50 million dollars and obtaining a public listing on NASDAQ. He also served as CEO of Luminant Biosciences, an oncology research company studying metabolic pathways to destroying cancer cells.Throughout his career, Mr. Demurjian has successfully completed strategic transactions with G.E., Stryker, Black & Decker Corp., and Crane Cams. Mr. Demurjian currently sits on the Board of Directors of the Susan G. Komen Foundation, the NYU board of advisors and has served in the past on the Board of Directors of Luminant Bio., Mikronite Tech & KCC. #Aspargo #MichaelDemurjian #DrugFormulation #PatientCompliance #LiquidOralSuspensions #Bioavailability #Pharmacokinetics #Pharamcodynamics #Pharmacology #Adherence #Sildenafil #Dimenhydrante #Statins #Metformin #PotassiumIodide #Antiemetics #Dysphagia #MeteredDose #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
Send us a textJoin us for a discussion about subclinical mastitis in dairy goats caused by non-aureus Staph species (NAS) with Dr. Michelle Buckley. This research was completed during her time as a post-doctoral associate at Iowa State University with support from the USDA National Institute of Food and Agriculture, Agricultural and Food Research Initiative Competitive Program, Mitigating Antimicrobial Resistance Across the Food Chain, Grant/Award Number: 2021-69015-33501. Dr. Buckley is currently an Assistant Professor of Clinical Practice at Texas Tech University: https://www.depts.ttu.edu/vetschool/about/meet-our-team/faculty/michelle-buckley/In this episode we discuss two drugs that can be used in an extra-label manner to address subclinical mastitis in dairy goats during the dry period: Orbenin DC (cloxacillin benzathine) and ToMORROW (cephapirin benzathine). Dr. Buckley's work evaluated how long it took for both drugs to leave the goats' bodies after administration in both meat and milk as well as how effective they were at curing subclinical mastitis due to non-aureus Staph. She also evaluated antimicrobial resistance development due to treatment with these long-acting intramammary products. The published work that we discuss is titled "Pharmacokinetics of long acting cephapirin and cloxacillin after intramammary administration in dairy goats" and it can be found in the Journal of Veterinary Pharmacology and Therapeutics here: https://onlinelibrary.wiley.com/doi/10.1111/jvp.13445Additional publications will be added to the episode notes as they become available. As part of this research, the Dairy Goat Extension and Education website was developed to provide veterinarians and producers with resources for ensuring antimicrobial stewardship and milk quality in dairy goats. This website includes short video training modules as well as electronic records templates and other useful resources: https://www.dairygoatextension.org/As we mention several times during this episode, the drug use discussed here is extra-label and will require extended withdrawal recommendations to avoid violative residues in the food supply after use. Please contact the Food Animal Residue Avoidance Databank for guidance here: http://www.farad.org/If your company or organization would like to sponsor an episode or if you have questions about today's show, email Office@AASRP.org
In this episode of Life Sciences 360, host Harsh Thakkar sits down with Marc Sheetz, Associate Dean of Research at Midwestern University's College of Pharmacy, to discuss the growing concern of antimicrobial resistance and the field of pharmacometrics. Marc sheds light on how pharmacometrics is shaping the future of medicine by using predictive models to personalize dosing, making drug treatments more effective while reducing toxicity. This episode dives deep into the intersection of pharmacometrics, AI, and machine learning, revealing how the future of patient care and treatment is rapidly evolving. Marc also shares insights from his current research in the infectious disease space, including his work with pediatric ICU patients.Chapters:00:00 Introduction00:03 Antibiotic Toxicity and Population Models01:02 The Importance of Antibiotics and Public Health Challenges01:22 Introduction to Pharmacometric Science03:12 Using Data in Medicine for Future Predictions06:01 Tailoring Drug Dosages for Individuals09:36 The Global Variation in Drug Dosages and Challenges14:44 The Future of Personalized Medicine and Precision Dosing21:39 The Intersection of AI, Machine Learning, and Pharmacometrics26:35 The Role of Technology in Medicine30:01 How Dosing Software and AI Are Enhancing Patient Care36:54 Innovation and Research Trends in Medicine- Connect with Marc Sheetz on Twitter: (https://twitter.com/IDPharmacometrics) - Learn more about Midwestern University: (https://www.midwestern.edu) - Follow Life Sciences 360 on LinkedIn (https://www.linkedin.com/company/life-sciences-360)--- Subscribe to our podcast for more insights on life sciences:
The New Student Pharmacist's Podcast Experience: Pharmacokinetics under the Bahamian Sun --- Note: The views of this podcast represent those of my guest(s) and I. -- Note: Purpose of these episodes- not at all, for advice or medical suggestions. These are aimed to provide support for peer pharmacists in training in educational and intellectually stimulating ways. Again, these are not at all for medical advice, or for medical suggestions. Please see your local state and board-certified physician, PA or NP, and pharmacist for medical advice and suggestions. ---
In this episode of the Boost Your Biology podcast, Lucas Aoun and Dave Watumull delve into the fascinating world of astaxanthin, a powerful antioxidant commonly derived from microalgae. They discuss its journey from discovery to supplementation, the extensive research backing its health benefits, and its unique mechanism of action that protects cellular membranes. The conversation also covers astaxanthin's potential in longevity research, its safety profile, and the evolution of its use in dietary supplements. Listeners will gain insights into how astaxanthin can enhance health and longevity, making it a valuable addition to their wellness regimen. In this conversation, Lucas Aoun and Dave Watumull delve into the multifaceted benefits of Astaxanthin, a powerful antioxidant. They discuss its safety profile, long-term health benefits, and its impact on athletic performance, skin health, and cardiovascular health. The conversation also touches on the potential effects of Astaxanthin on the microbiome and concludes with practical advice for supplementation.Check Out My Website For Coaching, Recommended Products and Much More:https://www.boostyourbiology.com/Buy High Quality Astaxanthin Here:https://glnk.io/5w7jn/ergogenic-healthCode: LUCAS20Chapters00:00 Introduction to Astaxanthin02:46 The Journey of Astaxanthin Research06:09 Evolution of Astaxanthin Supplementation09:01 Mechanism of Action: Antioxidant Properties11:58 Pharmacokinetics and Absorption14:53 Astaxanthin and Longevity Research17:55 Safety and Toxicology of Astaxanthin33:01 Safety and Toxicity of Astaxanthin36:54 Long-Term Benefits and Recommendations for Astaxanthin40:03 Astaxanthin's Impact on Athletic Performance55:32 Skin Health and UV Protection56:02 Cardiovascular Health Benefits of Astaxanthin01:04:30 Astaxanthin and the Microbiome01:07:04 Final Thoughts on AstaxanthinDisclaimer:The information provided in this podcast episode is for entertainment purposes and is NOT MEDICAL ADVICE. If you have any questions about your health, contact a medical professional. This content is strictly the opinions of Lucas Aoun and is for informational and entertainment purposes only. It is not intended to provide medical advice or to take the place of medical advice or treatment from a personal physician. All viewers of this content are advised to consult with their doctors or qualified health professionals regarding specific health questions. Neither Lucas Aoun nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this content. All consumers of this content especially taking prescription or over-the-counter medications should consult their physician before beginning any nutritional, supplement or lifestyle program. Hosted on Acast. See acast.com/privacy for more information.
Nathan Tamulis, Esq., Committee for Public Counsel Services, Boston teaches you how to interpret results (and knowing when to consult with an expert) from these methods and analyses, excerpted from MCLE's 4/2/2024 live webcast: Toxicology for Lawyers: Drug & Alcohol Testing. The full program is available as an on-demand webcast or an MP3 here. Get 24/7 instant access to hundreds of related eLectures like this one—and more—with a subscription to the MCLE OnlinePass. Learn more at www.mcle.org/onlinepass and start your free trial today! Connect with us on socials!Instagram: mcle.newenglandX (Formerly Twitter): MCLENewEnglandLinkedIn: Massachusetts Continuing Legal Education, Inc. (MCLE│New England)Facebook: MCLE New EngalndThreads: mcle.newnengland
Get ahead with VETAHEAD and join Dr. Proença on 15 minutes of ZooMed (exotic animal medicine) content. Today, let's explore the population pharmacokinetics of single-dose oropimobendan in ferrets. Discover how this chewable heart medication, commonly used for dogs, performs in our little fuzzy friends. From the challenges of administering medications to ferrets, to the fascinating findings on drug absorption and metabolism, this episode is packed with valuable insights and practical tips for veterinary professionals. Tune in to learn how oropimobendan could be a game-changer in managing cardiac conditions in ferrets and why cross-matching and individual variability are crucial considerations. Click here to receive a VETAHEAD Gift! Do you want to access more ZooMed (exotics) knowledge directly from specialists? Come with us and #jointhemovement #nospeciesleftbehind Head to VETAHEAD Website Join our VETAHEAD Community Follow @the_vetahead on Instagram Subscribe to @vetahead channel on YouTube Follow @vetahead on Facebook Follow @vetahead on TikTok
Joining us in this episode of Feedstuffs in Focus to discuss new research findings related to how quickly EXCEDE ® for Swine reaches therapeutic plasma concentration levels in pigs is Dr. Micah Jansen, Managing Technical Services Veterinarian for Zoetis Pork. Dr. Jansen details research presented at last fall's Leman Swine Conference and why it's relevant to veterinarians and pork producers when making antibiotic treatment decisions for swine respiratory disease.In addition to this podcast, we encourage you to learn more on the topic in our recent Feedstuffs 365 interview with Dr. Jansen.This episode of Feedstuffs in Focus has been brought to you by Zoetis PorkIMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to EXCEDE for Swine. Do not use in swine found to be hypersensitive to the product. Pre-slaughter withdrawal time is 14 days following the last dose. See full prescribing information at Excedeforswine.com/pi.References1 Lutz, S., et. al.; Pharmacokinetics of Ceftiofur Crystalline Free Acid; Leman 2023.2 Data on file, Study Report No. 1121R-60-04-215, Zoetis LLC.3 Anadón A. Perspectives in Veterinary Pharmacology and Toxicology. Front Vet Sci. 2016 Sep 13;3:82. doi: 10.3389/fvets.2016.00082. PMID: 27679801; PMCID: PMC5020047.4 Data on file, Study Report No ORPORK2030, Zoetis Services, LLC5 Bowersock, T.L., et al., Efficacy of Ceftiofur Crystalline Free Acid for the Treatment of Artificially-induce Pnemonia in an Actinobacillus Pleuropneumoniae Challenge Model. Proceedings of the 18th International Pig Veterinary Society Congress, Hamburg, Germany, 2004.6 Data on file, Study Report No. 1123C-60-08-315, Zoetis Services LLC7 EXCEDE for Swine FOI Summary: 2004/06/18 Original NADA 141-235.All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. Baytril is sold by Elanco or its affiliates and is not a product of Bayer. Baytril is a trademark owned by Bayer and used under license. © 2024 Zoetis Services LLC. All rights reserved. EXS-00072
One PK table to rule them allOne table to find themOne table to bring them all And in the darkness blind them… …with awesome antibiotic PK facts you can use to bedazzle your friends and enemies alike! Prep notes here. Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on X/Threads @IDiots_podPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod
Guidance Recap Podcast | Pharmacokinetics Study Design Considerations in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing
The last Pharmacokinetics episode had finally been …Excreted! This episode covers the ‘drug out' bit of pharmacokinetics, including things such as: -What is clearance? -how to calculate half life and -doesn't everything leave through the kidneys anyway? (That is sort of true, also shut up). Check out our prep notes (including for this episode) here. Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on X/Threads @IDiots_podPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod
It's the second Pharmacokinetics episode you never knew you wanted! Let's talk about how antibiotics are distributed around the body once absorbed, using the examples of Amoxicillin and CallumShutUpicillin (listen to episode for clarification).What exactly is the volume of distribution? Want a handy reference for the plasma protein binding of various antimicrobials? Then this is the episode for you! Check out our prep notes (including for this episode) here. Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on X/Threads @IDiots_podPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod
This podcast episode features Dr. Barbara Gunka and Dr. Siraj Mithoowani discussing their research on how bariatric surgery affects direct oral anticoagulants (DOACs).Bariatric surgery is increasingly used to fight obesity-related health problems. However, these patients often need DOACs to prevent blood clots due to surgery and obesity.The concern is that bariatric surgery might change how the body absorbs DOACs. This could make the medications less effective. There's limited data on long-term DOAC use after bariatric surgery.Dr. Gunka and Dr. Mithoowani's study investigated DOAC levels in patients after bariatric surgery. They looked at patients who received any type of bariatric surgery, took a DOAC for any reason, and had their DOAC levels measured afterwards.Tune in to hear the full discussion about the study's findings and their implications for DOAC use after bariatric surgery.Reference:Gunka, B., Mackenzie, D., Hughes, T., Sardo, L., Bayadinova, J., Siegal, D. M., ... & Mithoowani, S. (2024). Pharmacokinetics of direct oral anticoagulants after bariatric surgery: A retrospective cohort study. Thrombosis Research, 235, 15-17.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
Join me, Dr. Mike T. Nelson, on the Flex Diet Podcast, where we explore the fascinating world of exogenous ketones with Tecton's innovation head, Mike Chesney. Listen in as we unravel the science behind ketone esters, their remarkable ability to enhance cognitive function as an energizing alternative to caffeine, and their emerging role in disease management. We dissect the cutting-edge research and development propelling this field forward, and I share my unique perspective as a scientific advisor and ambassador for Tecton.Sponsors:See discounts for all the products I use and recommend: https://miketnelson.com/faves/Get a Free Sample Pack of all LMNT Flavours with your first box at http://drinklmnt.com/mikenelson (automatically applied at checkout)Friends of Mike, create an account and get 25% off your first order of Tecton: https://blog.tectonlife.com/ambassador/dr-mike-t-nelson/Phys Flex Cert opens March 18: http://www.physiologicflexibility.comEpisode Chapters:(0:00:00) - Exogenous Ketones for Health and Performance(0:09:22) - Military Experience and Ketone Development(0:19:37) - Neuroprotection and Exogenous Ketones(0:30:14) - Military DARPA Projects and Innovation(0:39:07) - Development of Ketone Ester From BHB(0:48:18) - The Benefits of Tecton Supplementation(1:00:03) - Benefits of Ketones in HealthEpisodes You Might Enjoy:Episode 253: Enduring the Arctic Chill and Unveiling the Power of Ketones with Akshay Nanavanti and Tecton Life: https://miketnelson.com/episode-253-enduring-the-antarctic-chill-and-unveiling-the-power-of-ketones-with-akshay-nanavati/ Flex Diet Podcast: Dr. Dom D'Agostino on Red Light, Ketones, Fasting, Zapping Monkeys and More: https://miketnelson.com/dr-dom-dagostino-on-red-light-ketones-and-more/ Episode 226: A Deep Dive into Ketones, Astaxanthin, and Cognitive Enhancement with Dr. Hunter Waldman: https://miketnelson.com/deep-dive-into-ketones-astaxanthin-and-cognitive-enhancement-dr-hunter-waldman/Get In Touch:Instagram: https://www.instagram.com/drmiketnelson/YouTube: https://www.youtube.com/channel/UCn1aTbQqHglfNrENPm0GTpgEmail: https://miketnelson.com/contact-us/
It's the Pharmacokinetics episode you never knew you wanted! Callum didn't know either, but never mind that let's talk about how antibiotics are absorbed, and how we can use that to improve our use of them in clinical practice. Want ammunition for that oral switch? Got someone who's doubting oral antibiotics' effectiveness? Then this is the episode for you! Check out our prep notes (including for this episode) here. Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on X/Threads @IDiots_podPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod
In this episode of the Psychedelic Medicine Podcast we discuss the topic of psychedelics and postpartum mood disorders. Melissa Whippo is a licensed psychotherapist who specializes in the intersection of women's health and psychedelics. She founded a non-profit, Deva Collective, which has fiscal sponsorship with MAPS, and is currently conducting research about perimenopause and microdosing San Pedro. In this conversation, Melissa shares the details of existing research into psychedelic treatments for postpartum populations. She discusses the findings from her study on “The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women,” reporting that ketamine was not detected at all in breast milk twelve hours after dosing. She also shares information on parents' intentional use of microdosing and what motivates them to take up this practice. In closing, Melissa discusses her upcoming research on microdosing San Pedro among perimenopausal populations and why she decided to focus on San Pedro for this study. In this episode you'll hear: The early research into ketamine for postpartum depression and whether ketamine remains in breast milk The prevalence of mood concerns in the postpartum population Issues of access with ketamine treatments for new mothers Improvements in postpartum mood patients following ketamine treatments that Melissa has seen in her practice Hormone changes after giving birth and how this might relate to mood concerns Ketamine for postpartum pain Quotes: “The reason why ketamine and other psychedelics appeal to me more [than other treatments for postpartum depression], is it's not a medicine you have to take every day and it's not a medicine that's going to cause a significant separation [with the newborn] like a hospital admission would.” [5:55] “More SSRI—which is still considered safe by the medical profession—passes through the breastmilk than ketamine. Probably nanograms. And ketamine has such a short half-life in the system, particularly with the intramuscular route of administration, that twelve hours after dosing, the breast milk was completely clear.” [14:22] “That's what ketamine does so well—it gives people a different view of some of the things they're really struggling with that they can't quite break through. Some of these more recursive ruminations that seem to befall mothers quite a bit—and they're usually pretty negative. But the medicine space gives them a different view.” [18:52] Links: Melissa's study: The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites Melissa's article in the Washington Post: Some moms are microdosing mushrooms for anxiety and depression Melissa's website Deva Collective website Melissa on Instagram Plant Parenthood website Previous episode: Psychedelics and Women's Health with Allison Feduccia, PhD Psychedelic Medicine Association Porangui
Numerous Population Pharmacokinetic (PopPK) models have been developed for Piperacillin (PIP), most of which are based on small monocentric studies and may not be generalizable to other populations. A recent evaluation of six PIP models in 30 ICU patients receiving CI demonstrated large inter-model variability regarding predictability. The transferability of these results to other populations is uncertain due to the limited number of patients and the monocentric setting. Furthermore, a clinically oriented model assessment in conjunction with TDM (Bayesian forecasting) was lacking. A recent study aimed to evaluate the predictive performance of available PIP PopPK models with and without TDM using an external multicenter dataset to facilitate model selection for MIPD in critically ill patients. Listen to the podcast and learn more about the methodology and findings of this study.
Unit 1 Kinetics and Dynamics 1_2 Pharmacokinetics This is a free open educational resource I am reading as an audio to make more accessible under Creative Commons Attribution 4.0 International License. While I am a licensed pharmacist, I am not providing any health advice, this is for educational purposes only. Here's my website: https://www.memorizingpharm.com/ Where you can get the Memorizing Pharmacology: A Relaxed Approach audiobook, possibly for free: https://www.audible.com/pd/Memorizing-Pharmacology-Audiobook/B09JVBHRXK?source_code=AUDFPWS0223189MWT-BK-ACX0-281667&ref=acx_bty_BK_ACX0_281667_rh_us OER Pharmacology Book Link to download or view the book presented in the video. https://wtcs.pressbooks.pub/pharmacology/ Want to get in touch with me, tonythepharmacist@gmail.com
Fascinating research out of the University of Michigan on L-carnitine and its relation to kidney function and outcomes in patients with septic shock. OPEN ACCESS to the full text manuscript at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.2882
The Elective Rotation: A Critical Care Hospital Pharmacy Podcast
Show notes at pharmacyjoe.com/episode888. In this episode, I’ll discuss how fluid overload affects the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis. The post 888: The Effects of Fluid Overload On the Pharmacokinetics of Extended Infusion Meropenem in Critically Ill Patients with Sepsis appeared first on Pharmacy Joe.
The Elective Rotation: A Critical Care Hospital Pharmacy Podcast
Show notes at pharmacyjoe.com/episode888. In this episode, I’ll discuss how fluid overload affects the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis. The post 888: The Effects of Fluid Overload On the Pharmacokinetics of Extended Infusion Meropenem in Critically Ill Patients with Sepsis appeared first on Pharmacy Joe.
About Anne Heatherington:Anne Heatherington is the R&D Chief Data and Technology Officer at Takeda, a top biopharmaceutical leader in Cambridge, Massachusetts. With over four years at Takeda, Anne leads the Data Sciences Institute team, steering the data, digital, and technology strategy for Research & Development. Her diverse career includes key roles such as Senior Vice President at Summit Therapeutics plc and Vice President at Pfizer. After 12 years at Pfizer, Anne chaired the Technical Review Committee, showcasing her leadership. Anne holds a Bachelor of Science in Pharmacy from Queen's University Belfast, a Ph.D. in Pharmacokinetics from the University of Manchester, and is a Senior Research Fellow at the University of Washington.Things You'll Learn:Drug development is at a critical point where marrying traditional approaches with new innovations is crucial to avoid obsolescence, emphasizing the need for adaptability in the industry.Takeda aims to become the most trusted digital biopharmaceutical company, driving innovation in the healthcare sector.Achieving success in digitalizing drug development involves combining knowledge of regulations, a strong foundation in science, and a dedication to innovation.It's more impactful to solve real-world problems with AI rather than just following the hype.Takeda collaborates with MIT, leveraging AI to address business problems and develop solutions, such as using speech as a biomarker for diseases.Resources:Connect with and follow Anne Heatherington on LinkedIn.Follow Takeda on LinkedIn and visit their website.
More information about Brain Lenses at brainlenses.com.BL supporters receive an additional episode of the show each week. Info about becoming a supporter at the above address, or at Understandary.com.Read the written version of this episode: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit brainlenses.substack.com/subscribe
DrJustin Talwar, Anesthesiology Resident at the University of Kentucky, discusses pharmacokinetics of volatile anesthetic agents.
Exploration of the pharmacology, efficacy and safety, drug interactions, and side effects of mitragynia speciosa Footnotes: For more on how to help our nation's veterans: https://www.va.gov/REACH/ Veteran crisis line: Dial 988 and press 1. Or text 838255. Seasonal Affectiveness Disorder. National Institute of Mental Health. https://www.nimh.nih.gov/health/publications/seasonal-affective-disorder Kentucky Ibogaine Initiative: https://www.kentuckyibogaineinitiative.com/ Huberman, Andrew. Mental Health Toolkit: Tools to bolster your mood and mental health. Huberman Lab [podcast]. 30 Oct 2023 References on Kratom: FDA and Kratom. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom. 21 July 2023. Gandhi D, et al. Kratom induced severe cholestatic liver injury histologically mimicking primary biliary cholangitis: a case report. World Journal of Hepatology. 27 Oct 2020; 12(10): 863-869. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643221/ Gianutsos G. The DEA Changes its mind on Kratom. https://www.uspharmacist.com/article/the-dea-changes-its-mind-on-kratom#:~:text=In%20making%20this%20determination%20on,safety%20for%20use%20under%20medical. US Pharmacist. 17 March 2017 Happy Hippo. https://happyhippo.com/blogs/kratom-blog/the-benefits-of-agmatine-sulfate-as-a-kratom-potentiator Jentsch MJ, Pippin MM. Kratom. Stat Pearls. 28 August 2023. https://www.ncbi.nlm.nih.gov/books/NBK585120/ Kratom. Natural Medicines Comprehensive Database. Updated 6 June 2023. Kratom. California Poison Control System. 22 June 2016. Rexer B. Is Kratom legal? Kratom legality by state. Sprout Health Group. https://www.sprouthealthgroup.com/substances/is-kratom-legal-by-state/ Settle A and Yang C. A Case of Severe Kratom Addiction Contributing to a Suicide Attempt. Cureus. 2022 Sept; 14(9): e29698. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616552/ Ya K, et al. Pharmacokinetics of mitragynine, a major analgesic alkaloid in kratom: a systematic review. 2019(43): 73-82. https://www.sciencedirect.com/science/article/abs/pii/S1876201819302114
Ming May Zhang, PharmD reviews pharmacokinetic considerations in extracorporeal membrane oxygenation. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
Clinical Journal of the American Society of Nephrology (CJASN)
Drs. Benjamin Adegbite and Evren Azeloglu discuss the results of their study, "Patient-Specific Pharmacokinetics and Dasatinib Nephrotoxicity," on behalf of their colleagues.
Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, and Joshua Myers, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for the treatment of osteoporosis. The two presentations are titled, “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102),” and “An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study.” Show notes are available at https://www.endocrine.org/podcast/enp73-a-robotic-teriparatide-pill-to-treat-osteoporosis — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast
Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, and Joshua Myers, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for the treatment of osteoporosis. The two presentations are titled, “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102),” and “An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study.” Show notes are available at https://www.endocrine.org/podcast/enp73-a-robotic-teriparatide-pill-to-treat-osteoporosis — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast
Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, and Joshua Myers, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for the treatment of osteoporosis. The two presentations are titled, “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102),” and “An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study.” For helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast.
In this episode, Kyle Molina, PharmD, BCIDP, provides an overview of treatment of skin and soft tissue infections (SSTIs) and challenges in practice. Listen as he gives perspectives on:Guideline recommendations for treatment of purulent and nonpurulent SSTIsLogistical challenges with IV and oral antibioticsPros and cons of various locations of careData supporting the safety and efficacy of long-acting lipoglycopeptides for treatment of SSTIsUse of long-acting lipoglycopeptides in special populations of interest, including patients with obesity, diabetes, and injection drug useOverall place in therapy of long-acting lipoglycopeptides for SSTIs Faculty:Kyle Molina, PharmD, BCIDPInfectious Diseases Clinical PharmacistScripps Green HospitalLa Jolla, CaliforniaLink to full program: CCO: https://bit.ly/3J4mg8hProCE: https://bit.ly/3P0vB4E
Join me in the second part of this conversation with Dr. Jill Krapf, LS specialist; researcher; author; and educator, about her research review, "Topical Corticosteroids in the Treatment of Vulvar Lichen Sclerosus: A Review of Pharmacokinetics and Recommended Dosing Frequencies." When evaluating treatments for lichen sclerosus, one must consider all variables involved for optimal application. In this review article, the authors explore the science of the skin and the effects of inflammation, as well as the absorption of the medication. However, with limited research guiding us, the answer remains scattered and uncertain, leaving us with more questions than answers. In this episode, you will be able to: Discover the effectiveness of topical steroid treatments in managing Lichen Sclerosus. Understand skin absorption concerns and dosages when using steroid treatments. Uncover truths about the myths surrounding the long-term side effects of steroid use. Grasp the significance of adhering to proper steroid application guidelines. Delve into alternative treatment options beyond steroid usage for Lichen Sclerosis. My special guest is Dr. Jill Krapf Dr. Jill Krapf is a renowned researcher, author, vulvar specialist, and educator with a passion for helping patients suffering from Lichen Sclerosus. Her extensive knowledge and experience in the field make her an invaluable resource for those seeking guidance on steroid treatments for Lichen Sclerosus. Dr. Krapf's dedication to uncovering the most effective methods of treatment has led her to conduct in-depth research on the impact of steroids on Lichen Sclerosus patients. With a wealth of experience and expertise, Dr. Krapf is an ideal guest to shed light on this complex topic and provide much-needed answers to those affected by this condition. The key moments in this episode are: 00:00:00 - Introduction, 00:02:26 - Types of Research, 00:07:45 - Purpose of the Review, 00:13:08 - Absorption of Topical Steroids, 00:15:57 - Understanding Lichen Sclerosis Skin, 00:17:42 - Interpreting the Effects of Inflammation on Skin, 00:19:27 - Burnt Out Lichen Sclerosis and Hyperpigmentation, 00:22:05 - Risks of Topical Steroids, 00:25:48 - Thinning of the Skin, 00:31:57 - Misuse of Steroids, 00:33:23 - Side Effects of Steroid Use, 00:36:02 - Tapering Medications, 00:37:37 - Current Steroid Use Guidelines, 00:39:32 - CO2 Laser and Steroid Injections, 00:43:05 - Conclusion, Check out all the ways Lichen Sclerosus Support Network can help you at lssupportnetwork.org. Resources: Vulvar Lichen Sclerosus: Current Perspectives https://www.vulvodynia.com/assets/files/ijwh-191200-vulvar-lichen-sclerosus-current-perspectives.pdf Topical Corticosteroids in the Treatment of Vulvar Lichen Sclerosus: A Review of Pharmacokinetics and Recommended Dosing Frequencies https://vulvodynia.com/assets/files/Lichen-Sclerosus.pdf Center for Vulvovaginal Disorder http://cvvd.org LSSN Blogs: How to Apply Topical Steroid Treatment for Lichen Sclerosus Correctly https://lssupportnetwork.org/applyproper Lichen Sclerosus Treatment Series Part 1: Steroids https://lssupportnetwork.org/steroids1 Lichen Sclerosus Treatment Series Part 2: Steroids https://lssupportnetwork.org/steroids2 LSSN Video: Unraveling the Mystery of Lichen Sclerosus Treatment with Dr. Jill Krapf https://www.youtube.com/watch?v=NtFse-rcRwI How to Apply Topical Steroid Treatment for Lichen Sclerosus Correctly https://lssupportnetwork.org/drjill Connect with us: Instagram: https://www.instagram.com/lichensclerosussupportnetwork/ Facebook: https://www.facebook.com/lichensclerosussupportnetwork/ Website: https://lssupportnetwork.org/ Loved this episode? Make a donation to help us create new content. https://lssupportnetwork.org/donate
SOURCES: Police: Dentist killed wife by lacing shakes with poisonDentist Poisoned Wife to Death to Start 'New Life' With Paramour, Cops Allegehttps://s3.documentcloud.org/documents/23718101/23cr664-craig-james-toliver_redacted.pdfOleandrin: A Systematic Review of its Natural Sources, Structural Properties, Detection Methods, Pharmacokinetics and Toxicology - PMC.Dentist Poisoned Wife to Death to Start 'New Life' With Paramour, Cops AllegeJust a Pinch of Cyanide: The Basics of Homicidal Poisoning Investigations | Office of Justice Programs.Murder By Poison | The New YorkerWho was Colorado dentist James Craig's wife Angela and how many children did they have? | Daily Mail Online
The practice of critical care cardiology relies on the use of invasive hemodynamics, mechanical ventilation, mechanical circulatory support, and other advanced techniques to help our patients recover from critical cardiac illnesses. To facilitate these interventions, it is essential to have a broad understanding of how sedation and analgesia keep our patients comfortable and safe throughout their time in the CICU. In this episode, series co-chair, Dr. Yoav Karpenshif, and CardioNerds co-founder, Dr. Daniel Ambinder, are joined by Dr. Natalie Tapaskar, cardiology fellow and CardioNerds FIT Ambassador from Stanford, and faculty expert, Dr. Chris Domenico, to discuss sedation in the cardiac ICU. Notes were drafted by Dr. Natalie Tapaskar. Audio editing by CardioNerds academy intern, Anusha Gandhi. We discuss the use of analgesics and sedative medications in the cardiac ICU. We dissect three cases of VT storm, heart failure associated cardiogenic shock, and cardiac arrest. We assess the hemodynamic, arrhythmic, and metabolic effects of opioids and sedatives and delve into the altered pharmacokinetics of these drugs during targeted temperature management. Most importantly, we highlight the use of structured pain and sedation scoring systems and discuss the recognition and management of ICU delirium both from a pharmacologic and non-pharmacologic standpoint. The CardioNerds Cardiac Critical Care Series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Mark Belkin, Dr. Eunice Dugan, Dr. Karan Desai, and Dr. Yoav Karpenshif. Pearls • Notes • References • Production Team CardioNerds Cardiac Critical Care PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Sedation in the Cardiac ICU with Dr. Christopher Domenico Think about analgesia and sedation as separate entities with management of analgesia first and sedation second. Frequent re-assessment of needs should be performed to reduce ICU delirium and improve long-term outcomes. Fentanyl is generally a good starting point for analgesia in the ICU since it is fast on/fast off, but can stick around for a long time the longer it is used. The choice of bolus or continuous infusion opioids depends on the clinical scenario and personal/institutional preference. Remember to administer bolus doses that are 50-100% of the hourly continuous infusion dose to reach steady state faster. When managing refractory VT storm with sedative agents (propofol, benzodiazepines and/or dexmedetomidine), you should target the deepest level of sedation necessary to suppress sympathetic drive. For cardiogenic shock patients, the choice of sedative agent is a nuanced decision. Think about etomidate first for intubation as it has the least cardiovascular and hemodynamic impact. And remember the propofol trifecta: negative inotropy, direct vasodilation, and bradycardia! Pharmacokinetics are disrupted during targeted temperature management, thus be weary of overly sedating patients due to reduced drug clearance. Show notes - Sedation in the Cardiac ICU with Dr. Christopher Domenico How do we initiate analgesics and sedatives? Analgesia first and sedation second! Analgesia: think about how to reduce a patient's painEveryone has a different pain tolerance and critically ill patients can have moderate to severe pain at baseline. Metrics to assess pain include self-reported scales, behavioral scales, facial expressions, extremity movement, compliance with the ventilator, tachycardia, tachypnea, and hypertension. Sedation: think about how to reduce a patient's agitation or anxietyThe target depth of sedation depends on the clinical scenario.For example,
This common pharmacokinetic reaction will help you manage many of bad medication reactions in psychiatric practice. But did it lead to Elvis Presley's death? Publication Date: 2/6/2023Duration: 23 mins, 26 secondsChris Aiken, MD, and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Sponsor special: Up to $2,500 of FREE silver AND a FREE safe on qualifying orders - Call 855-862-3377 or text “AMERICAN” to 6-5-5-3-2“There's a loophole that they've slipped through in the regulatory process, because most drugs require pharmacokinetic studies … And that has not been done with the COVID-19 vaccines,” says Dr. Tess Lawrie, co-founder of the World Council for Health.Pharmacokinetics is the study of how a drug behaves in a patient's body, how it distributes, and how long it takes to be cleared from the body. “Because they've been called vaccines … all these manufacturers have been required to do is to show that the product they inject gives an immune reaction, gets an immune response. They have not been required to show how it distributes around the body,” says Lawrie.She argues that the COVID-19 injections are not actually vaccines, but are instead gene therapies. And they must be halted immediately, she says.Myocarditis is just the tip of the iceberg. Inflammation is actually occurring not just in the heart, but “in every organ and tissue of the body,” Lawrie says.In this episode, she breaks down the alarming signals that independent researchers have found, and what people can do if they are worried about their own health or the health of their loved ones.Dr. Lawrie is also the director of The Evidence-Based Medicine Consultancy Ltd. Her Substack is called “A Better Way to Health.”
On this week's podcast, Drs.Feigenbaum and Baraki talk about the he effects of coffee and caffeine on health and performance. References: Cornelis MC. The Impact of Caffeine and Coffee on Human Health. Nutrients. 2019;11(2):416. Published 2019 Feb 16. doi:10.3390/nu11020416 Del Coso J, Lara B, Ruiz-Moreno C, Salinero JJ. Challenging the Myth of Non-Response to the Ergogenic Effects of Caffeine Ingestion on Exercise Performance. Nutrients. 2019;11(4):732. Published 2019 Mar 29. doi:10.3390/nu11040732 Institute of Medicine (US) Committee on Military Nutrition Research. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington (DC): National Academies Press (US); 2001. 2, Pharmacology of Caffeine. Grgic J, Trexler ET, Lazinica B, Pedisic Z. Effects of caffeine intake on muscle strength and power: a systematic review and meta-analysis. J Int Soc Sports Nutr. Mar 2018;15:11. Grgic J, Grgic I, Pickering C, et al. Wake up and smell the coffee: caffeine supplementation and exercise performance—an umbrella review of 21 published meta-analyses. British Journal of Sports Medicine. March 2019 Skinner, Tina L, et al. “Women Experience the Same Ergogenic Response to Caffeine as Men.” Medicine and Science in Sports and Exercise, vol. 51, no. 6, 2 June 2019, pp. 1195–1202., Waller G, Dolby M, Steele J, Fisher JP. A low caffeine dose improves maximal strength, but not relative muscular endurance in either heavier-or lighter-loads, or perceptions of effort or discomfort at task failure in females. PeerJ. 2020;8:e9144. Published 2020 May 14. doi:10.7717/peerj.9144 White JR Jr, Padowski JM, Zhong Y, et al. Pharmacokinetic analysis and comparison of caffeine administered rapidly or slowly in coffee chilled or hot versus chilled energy drink in healthy young adults. Clin Toxicol (Phila). 2016;54(4):308-312. doi:10.3109/15563650.2016.1146740 Wickham KA, Spriet LL. Administration of Caffeine in Alternate Forms. Sports Med. 2018;48(Suppl 1):79-91. doi:10.1007/s40279-017-0848-2 McGuire S. Institute of Medicine. 2014. Caffeine in Food and Dietary Supplements: Examining Safety—Workshop Summary. Washington, DC: The National Academies Press, 2014. Adv Nutr. 2014;5(5):585-586. doi:10.3945/an.114.006692 Duncan Turnbull, Joseph V. Rodricks, Gregory F. Mariano, Farah Chowdhury, Caffeine and cardiovascular health, Regulatory Toxicology and Pharmacology, Volume 89, 2017, Pages 165-185, ISSN 0273-2300, https://doi.org/10.1016/j.yrtph.2017.07.025. Lorenzo Calvo, J.; Fei, X.; Domínguez, R.; Pareja-Galeano, H. Caffeine and Cognitive Functions in Sports: A Systematic Review and Meta-Analysis. Nutrients 2021, 13, 868. https://doi.org/10.3390/nu13030868 WheyRx https://www.barbellmedicine.com/shop/supplements/gainzzz-rx-whey-protein-isolate/ Seminars https://www.barbellmedicine.com/seminars/ For more of our stuff: App: https://tinyurl.com/muus5pfn Podcasts: goo.gl/X4H4z8 Website: www.barbellmedicine.com Instagram: @austin_barbellmedicine @jordan_barbellmedicine @leah_barbellmedicine @vanessa_barbellmedicine @untamedstrength @derek_barbellmedicine @hassan_barbellmedicine @charlie_barbellmedicine @alex_barbellmedicine @tomcampitelli @joe_barbellmedicine @rheece_barbellmedicine @cam_barbellmedicine @claire_barbellmedicine @ben_barbellmedicine @cassi.niemann @caleb_barbellmedicine Email: info@barbellmedicine.com Supplements/Templates/Seminars: www.barbellmedicine.com/shop/ Forum: forum.barbellmedicine.com/
© 2020-2025 Ivy Podcast Discovery LLC
